Search Bar & Filters
Found 53 Actively Recruiting clinical trials
Actively Recruiting
Researchers are evaluating AZD0780, an oral PCSK9 inhibitor, in a phase 3 randomized, double-blind, placebo-controlled study to assess its effect on reducing major adverse cardiovascular events in patients with established atherosclerotic cardiovascular disease ASCVD or those at high risk for a first ASCVD event. The study compares AZD0780 with a placebo and is event-driven, focusing on time to first cardiovascular events over approximately 54 months. Participants will be randomly assigned to receive either oral AZD0780 once daily or a matching placebo once daily. The study treatment continues from randomization until the primary analysis censoring date, followed by a study closure visit which marks the final visit for each participant. Background lipid-lowering therapy is maintained and expected to achieve significant LDL cholesterol reduction. The study design includes parallel treatment groups with quadruple masking to ensure unbiased results. During the study, participants attend regular visits for monitoring and assessments over a period that can last up to about 54 months. Researchers will measure the time to first major cardiovascular events including heart attack, stroke, urgent coronary revascularization, cardiovascular death, and other related outcomes. Safety and efficacy are carefully monitored through clinical evaluations, laboratory tests, and patient follow-up until study completion.
Actively Recruiting
Researchers are evaluating the safety and effectiveness of tezepelumab, a biological drug, in adults aged 40 to 80 with moderate to very severe chronic obstructive pulmonary disease COPD. This Phase 3, randomized, double-blind, placebo-controlled study includes participants who have experienced worsening COPD symptoms despite inhaled maintenance therapy. The study aims to reduce the rate of moderate or severe COPD exacerbations, which are episodes when symptoms worsen significantly. Participants will receive monthly subcutaneous injections of either one of two doses of tezepelumab or a matching placebo for a minimum of 52 weeks and up to 76 weeks. After the treatment period, there is a 12-week safety follow-up without treatment. The study compares tezepelumabs effects to placebo to evaluate its impact on lung function, COPD symptoms, and exacerbation frequency. Throughout the study, participants will undergo regular assessments including lung function tests, symptom questionnaires, and blood tests to monitor immune response and drug levels. Researchers will track COPD exacerbations and quality of life changes using tools like the St. Georges Respiratory Questionnaire and COPD Assessment Test. Safety will be monitored during and after treatment, with the entire participation lasting up to about 88 weeks including follow-up.
Actively Recruiting
Researchers are evaluating the safety and effectiveness of the AlphaReturn Blood Management System used together with the AlphaVac Multipurpose Mechanical Aspiration MMA System for treating acute pulmonary embolism. This prospective, multicenter, single-arm study focuses on patients with acute intermediate-risk pulmonary embolism confirmed by computed tomography angiography CTA and specific clinical signs. The study aims to assess device-related adverse events and the technical success of the procedure. Participants will undergo mechanical thrombectomy using the AlphaVac MMA System. After the procedure, the aspirated blood will be filtered through the AlphaReturn Blood Management System and reinfused back into the patient. This investigational device study involves a single treatment group using these combined systems to manage blood during the intervention. During the study, participants will be closely monitored for device-related adverse events up to 30 days after the procedure. Additional assessments include tracking major adverse events, complications, symptomatic pulmonary embolism recurrence, reduction in right ventricle to left ventricle RVLV ratio, use of thrombolytics, and length of stay in intensive care and hospital. Safety and effectiveness outcomes will be collected throughout the follow-up period to evaluate the procedures impact and participant health.
Actively Recruiting
Researchers are evaluating the safety and effectiveness of the Edwards SAPIEN X4 and X4S Transcatheter Heart Valves in people with severe, symptomatic calcific aortic stenosis. This is a prospective, single-arm, multicenter study that includes a separate registry for subjects with bicuspid aortic valve morphology. The study aims to provide important data on these balloon-expandable bioprosthetic valves in this patient population. Participants will undergo a transcatheter aortic valve replacement TAVR procedure using either the SAPIEN X4 or SAPIEN X4S valve. Those with bicuspid aortic valves will be enrolled in a separate registry and also undergo TAVR. The study involves implantation of the valve device via catheter, with no randomization or comparison groups. The primary study period extends up to one year after the procedure. During the study, participants will be monitored through regular assessments including evaluation of survival and stroke occurrence at one year. Secondary outcomes include quality of life measured by the Kansas City Cardiomyopathy Questionnaire, paravalvular leak assessment at 30 days, and new permanent pacemaker implantation also at 30 days. Edwards Lifesciences sponsors the study, and participants will be followed until study completion in 2037 to monitor safety and effectiveness outcomes.
Actively Recruiting
Researchers are evaluating the use of apixaban compared to aspirin to prevent stroke or death in patients who have had a recent intracerebral hemorrhage ICH and also have atrial fibrillation AF. This phase III randomized, double-blinded trial aims to determine if apixaban is superior in preventing any type of stroke or death, as well as if it leads to better functional recovery measured by the modified Rankin Scale. The study will enroll 700 patients and follow them for 12 to 36 months to assess these outcomes. Participants will be randomly assigned to receive either apixaban or aspirin. Apixaban dosing is typically 5 mg twice daily, with a reduced dose of 2.5 mg twice daily for those meeting specific criteria such as older age, lower body weight, or certain medication use. Aspirin is given once daily at a dose of 81 mg. The study includes a treatment period after recent ICH, with careful monitoring for safety and efficacy. During the study, participants will undergo regular assessments including evaluation of stroke occurrence, death, and changes in functional status using the modified Rankin Scale. Safety and adherence will be monitored throughout the follow-up period, which ranges from 12 months up to 3 years. The research team will collect data to understand the benefits and risks of apixaban versus aspirin in this patient population.
Actively Recruiting
Researchers are studying adults newly diagnosed with breast, colorectal, melanoma, non-Hodgkin lymphoma, or non-small cell lung cancers who are starting systemic cancer treatments such as chemotherapy or immune checkpoint inhibitors. The purpose is to understand how cannabis and cannabinoid use relates to cancer-related symptoms over one year. This observational study enrolls 2000 participants to explore these associations in community oncology settings. Participants do not receive any experimental treatments but complete surveys and have their medical records reviewed. Assessments occur monthly for up to 12 months, capturing cannabis use, perceived benefits and harms, and adverse effects alongside symptom tracking. There is an optional sub-study for some participants receiving immune checkpoint inhibitors at specific cancer centers. During the study, participants complete monthly surveys either online at home, in clinic, or other locations, and their medical records are reviewed for treatment and symptom information. Researchers measure cancer-related symptoms and cannabis use patterns over time. The study monitors participants for up to one year to evaluate symptom changes and cannabis-related effects, with no intervention administered by the study team.
Actively Recruiting
Researchers are comparing how quickly people with high blood pressure and intracerebral hemorrhage ICH can reach a stable target systolic blood pressure SBP within 60 minutes using two different intravenous treatments. The study focuses on patients with acute stroke symptoms and elevated SBP between 150 and 220 mmHg, aiming to evaluate the effectiveness of clevidipine versus other standard IV antihypertensive regimens. This research is sponsored by the Zeenat Qureshi Stroke Institute and involves adults aged 18 to 100 years. Participants receive either IV clevidipine or an alternate IV antihypertensive medication depending on the hospital type. Clevidipine dosing starts at 1-2 mghour and is adjusted frequently to reach the blood pressure goal, with dose increases slowing as the target is approached. Doses typically range from 4-6 mghour, with a maximum infusion volume limit to avoid lipid overload. The alternate regimen often involves IV nicardipine, starting at 5 mghour and adjusted as needed per FDA guidelines. Treatment initiation occurs within 12 hours of neurological symptom onset. During the study, participants undergo blood pressure monitoring every 15 minutes to assess stability and response to treatment. Eligibility includes clinical stroke signs and confirmed brain hematoma on CT scan, with follow-up visits planned at 90 and 180 days after enrollment. Informed consent is required, and patients undergoing surgical or drainage interventions under guideline timing are included unless surgery is performed within 6 hours of treatment start. Safety and treatment effects are carefully tracked throughout the study period ending in 2028.
Actively Recruiting
Healthy Volunteer
Researchers are collecting blood and tissue samples from people with and without cancer to help develop and evaluate tests for early cancer detection. This observational study aims to create a blinded reference set of blood samples from cancer and non-cancer patients to validate new blood-based multi-cancer early detection tests. The study also evaluates test performance at the time of initial cancer diagnosis by tumor type and clinical stage. Participants complete a questionnaire at the start of the study and provide blood samples at registration and again 12 months later. Patients diagnosed with cancer may also provide tissue samples at these same times. The study collects these biospecimens to help researchers study and validate early cancer detection assays in the laboratory. During the study, participants are monitored with follow-up at one year after enrollment. Researchers assess the quality and usefulness of the collected blood samples as a blinded reference set for cancer detection tests. The main outcome is the provision of these samples over up to one year, with additional evaluation of test performance by tumor type and stage. Participants involvement includes questionnaires, blood draws, and possible tissue sample collection, with no treatment interventions involved.
Actively Recruiting
Researchers are collecting biological samples and medical data from patients who experience serious side effects after receiving immunotherapy treatments for cancer. This observational study aims to build a national collection of these samples and data to help future research better predict, prevent, and manage these immune-related adverse events, rare infections, or rapid tumor growth. Participants provide tissue, blood, and optionally stool samples if they experience colitis, shortly after confirmation of a severe immune-related side effect and again one month later. Their medical records will be reviewed for up to one year to gather detailed clinical information. This study does not involve administering treatments but focuses on collecting data and samples from those already treated with immuno-oncology therapies. During the study, participants undergo sample collections at registration and one month later. Researchers will review medical records over a year to monitor health outcomes and side effects. The main measurement is establishing the biorepository of samples and data for future studies. Participation duration can last up to one year with periodic assessments based on medical record review and sample collection.
Actively Recruiting
Researchers are evaluating how to best recommend chemotherapy for patients with colon cancer based on the presence or absence of circulating tumor DNA ctDNA after surgery. This Phase IIIII trial aims to determine if ctDNA can be used to better identify patients who need adjuvant chemotherapy and to assess optimal chemotherapy regimens for those with detectable ctDNA, as current biomarkers have not been prospectively validated. Participants are assigned to different groups based on their ctDNA status after surgery. Those without detectable ctDNA may undergo serial ctDNA monitoring without treatment or receive shorter chemotherapy regimens. Patients with detectable ctDNA receive more intensive chemotherapy options, including combinations of oxaliplatin, leucovorin, 5-fluorouracil, irinotecan, or capecitabine, administered intravenously or orally over cycles lasting several weeks. The study includes randomization and uses the Signatera test for central ctDNA detection. During the study, participants will undergo regular blood tests for ctDNA status, imaging scans, and clinical assessments. Researchers will track ctDNA positivity over up to 3 years and disease-free survival over up to 5 years. Other measures include overall survival, recurrence rates, and chemotherapy compliance. The total study duration may extend several years with ongoing monitoring to evaluate safety and treatment outcomes.
1-10 of 53
1